Clinical trials: Crohn's Disease Colon
Ulcerative Colitis, Crohn's Disease
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).
- Trial name
- FENNEL (NCT03478956)
- Testing
- Etrolizumab
- Where
- 5 sites in Belgium, Poland and 2 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis, Crohn's Disease
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease
This was an open-label study to provide an opportunity for participants with Ulcerative Colitis (UC) who previously completed Study C13002 (NCT01177228), and for treatment-naïve participants with UC or Crohn's Disease (CD) to…
- Trial name
- NCT00619489
- Testing
- vedolizumab
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Granulomatous Colitis, Crohn's Disease
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.
- Conditions
- Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis
- Trial name
- NCT03599622
- Testing
- BMS-986165
- Where
- 259 sites in United States, Australia and 24 more
- Volunteers
- 239 people
- Sponsor
- Bristol-Myers Squibb
Ulcerative Colitis, Crohn's Disease
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
The main aim of the study is to learn if 4-weekly vedolizumab improves symptoms of Japanese participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD).
- Trial name
- NCT04738942
- Testing
- Vedolizumab
- Where
- 20 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Ulcerative Colitis, Crohn's Disease
Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate
Iron deficiency anaemia is common in inflammatory bowel disease (IBD), affecting at least 20% patients at any one time. Hepcidin, a recently described anti-microbial peptide synthesized by the liver, is a key regulator of iron…
- Trial name
- NCT01991314
- Testing
- Ferrous sulphate
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- Queen Mary University of London
Inflammatory Bowel Diseases, Ulcerative Colitis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
- Trial name
- CONNECT-IBD (NCT02539368)
- Testing
- CT-P13, Remicade
- Where
- 140 sites in Belgium, Czechia and 11 more
- Volunteers
- 2,565 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid, Colitis, Ulcerative
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.
- Conditions
- Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis
- Trial name
- NCT05796245
- Where
- Japan
- Volunteers
- 2,207 people
- Sponsor
- Pfizer
Colitis, Ulcerative, Inflammatory Bowel Diseases
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
The investigators will test the hypothesis that that greater efficacy of anti-tumor necrosis factor (antiTNF) therapy results in reduced need for bowel resection surgery, fewer serious infections, and reduced short term mortality…
- Conditions
- Colitis, Ulcerative, Inflammatory Bowel Diseases, Crohn's Disease
- Trial name
- PPOD (NCT02316678)
- Testing
- No intervention
- Where
- United States
- Volunteers
- 9,573 people
- Sponsor
- University of Pennsylvania
Inflammatory Bowel Disease, Ulcerative Colitis
Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care
The investigators hypothesize that outpatient clinical care of Inflammatory Bowel Disease patients may be provided using a new computerized system over standard network - called Collaborative Imaging - with similar patient…
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
- Trial name
- NCT01296841
- Testing
- Collaborative Imaging
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- VA Palo Alto Health Care System
Crohn's Disease
PillCam® Platform With the PillCam Crohn's Disease Capsule
This is a prospective, multi-center (up to 6 sites) study which aims to To establish the effectiveness of the PillCam Platform with the PillCam Crohn's capsule as demonstrated by visualizing the small bowel and colon in patients…
- Trial name
- NCT01631435
- Testing
- Pillcam colon capsule and PillCam™ Prep Procedure, Ileocolonoscopy
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Medtronic - MITG
Crohn's Disease
Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients
The proposed study is designed to evaluate Pillcam regimen in Crohn's disease patients, using the PillCam Colon system.
- Trial name
- RD-207 (NCT01576120)
- Testing
- bowel prep regimen first boost 6 oz. and second boost 3 oz., bowel prep regimen first boost 3 oz. and second boost 6 oz.
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Medtronic - MITG
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
Anal Human Papillomavirus in Inflammatory Bowel Disease Study
This is an observational cohort study with two time points (baseline and after at least 6 months of treatment with a non-corticosteroid immunosuppressive agent for inflammatory bowel disease (IBD)).
- Conditions
- Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease (CD), Anal Human Papillomavirus
- Trial name
- AnalHPV&IBD (NCT01364896)
- Testing
- Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Pittsburgh
Crohn's Disease
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease
The purpose of this study is to assess long-term safety data of GED-0301 for a period of up to 208 weeks in adult subjects (i.e., ≥ 18 years of age) who participated in the core Phase 3 GED-0301-CD-002 and GED-0301-CD-003 studies…
- Trial name
- NCT02641392
- Testing
- GED-0301
- Where
- 231 sites in United States, Australia and 29 more
- Volunteers
- 310 people
- Sponsor
- Celgene
Crohn's Disease
Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease
The study will examine the safety and effectiveness of brodalumab for the treatment of moderate to severe Crohn's disease. Participants will randomly assigned to receive either brodalumab or placebo (a lookalike liquid that…
- Trial name
- NCT01150890
- Testing
- Brodalumab
- Where
- 50 sites in United States, Australia and 6 more
- Volunteers
- 130 people
- Sponsor
- Amgen
Ulcerative Colitis, Crohn's Disease
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
This study will evaluate the long-term safety and tolerability of UTTR1147A in participants with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD), enrolling up to 320 participants from the parent studies: Phase…
- Trial name
- NCT03650413
- Testing
- UTTR1147A
- Where
- 57 sites in United States, Bulgaria and 12 more
- Volunteers
- 143 people
- Sponsor
- Genentech, Inc.
Inflammatory Bowel Diseases, Clostridium Difficile Infection
ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI
This is a randomized controlled trial to assess the clinical and microbiological impacts of FMT in combination with Bezlotoxumab (bezlo) compared to FMT in combination with placebo in patients with both inflammatory bowel disease…
- Trial name
- ICON-2 (NCT03829475)
- Testing
- Bezlotoxumab, Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Brigham and Women's Hospital
Colon Carcinoma, Dysplasia in Crohn Disease
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
This pilot, randomized phase I/II trial studies how well inositol works in preventing colorectal cancer in patients with abnormal cells (dysplasia) associated with inflammation of the colon (colitis).
- Conditions
- Colon Carcinoma, Dysplasia in Crohn Disease, Low Grade Dysplasia in Ulcerative Colitis, Rectal Carcinoma
- Trial name
- NCT01111292
- Testing
- Inositol
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Crohn's Disease, Ulcerative Colitis
Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)
The purpose of this study is to assess effectiveness of vedolizumab versus ustekinumab in patients with Crohn's disease and vedolizumab versus tofacitinib in patients with ulcerative colitis, after non-response to anti-tumor…
- Trial name
- COMPARE (NCT04852666)
- Where
- 2 sites in United States
- Volunteers
- 465 people
- Sponsor
- University of North Carolina, Chapel Hill
Crohn's Disease
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
- Trial name
- NCT01199302
- Testing
- Brodalumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Amgen
Crohn's Disease, Ileitis
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Study is designed to show a lack of effect on white blood cells circulating in the spinal fluid.
- Conditions
- Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Disease, Granulomatous Colitis
- Trial name
- TOSCA (NCT01387594)
- Testing
- lumbar puncture
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Shire